2005

15 December 2005
Santhera starts European Phase lll Study with its Lead Compound SNT-MC17 (idebenone) in Friedreich´s Ataxia

30 November 2005
Novaled GmbH raised €15 Million in its 2nd Round of Financing to commercialize its proprietary PIN OLED technology and material and to extend its world leading position in developing highly power efficient and long lifetime OLEDs.

15 November 2005
IDEA AG presents positive PH lll data for IDEA-033,
a targeted analgesic, at the annual scientific meeting of the American College of Rheumatology

14 November 2005
m-phasys and Fraunhofer Institute to collaborate on GPCR Antibodies for Therapeutic and Diagnostic use

03 November 2005
Novaled, the world leader in efficiency for OLEDs achieved a new record for a top-ermitting OLED. A saturated green was ermitted with an unsurpassed current efficiency of 95 cd/A (calenda per ampere).

28 September 2005
21.7% shareholding purchased in Europe´s leading targeted therapeutics company. IDEA prepares to expand its late stage clinical development programmes

18 August 2005
Novaled: Red OLED at 500 Candela m²
with lifetime exceeding 100,000 hours

14 July 2005
Blue Membranes closes its 2nd round financing after the technology buy-out in late 2003

20 June 2005
m-phasys GmbH in Tübingen receives Euro 1.4 million from the BMBF for protein structure analysis

09 May 2005
Philips and Novaled announce new record for efficiency of High-Brightness white oleds

May 2005
IDEA AG starts phase III study with IDEA-033
Largest clinical study executed to date by a german biotech firm

April 2005
Dietmar Hopp Again Invests in a Heidelberg Biotech Company
febit biotech GmbH Founded in April 2005

24 March 2005
Cenix BioScience Publishes Comprehensive Genome-Wide RNAi Screen of C. elegans Cell Division Genes and Releases Full Dataset Online

Spring 2005
IDEA AG Newsletter

28 February 2005
Cenix BioScience and Schering AG Sign Research Agreements to Advance Several Disease Programs

24 February 2005
Santhera Reaches Milestone in Serono Drug Discovery Collaboration

08 February 2005
m-phasys Completes Series C Financing and Sets Up New Business Unit "Therapeutic Anti-GPCR-Anitbodies"